| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular Medicine |
From the Division of Surgical Science, Department of Surgery, Columbia University Medical Center, New York.
Correspondence to Dr Shi-Fang Yan, Division of Surgical Science, Department of Surgery, College of Physicians and Surgeons of Columbia University, 630 W 168th St, New York, NY 10032. E-mail sy18{at}columbia.edu
| Abstract |
|---|
|
|
|---|
Key Words: cardiovascular endothelial cells hypoxia RAGE signal transduction
| Introduction |
|---|
|
|
|---|
| Materials and Methods |
|---|
|
|
|---|
Induction of Hypoxia in the Primary Cultured Murine Aortic Endothelial Cells and Human Aortic Endothelial Cells
Three lines of RAGE–/– and RAGE+/+ murine aortic endothelial cells (MAECs) were established from 3 individual mouse aortas as described.21 Human aortic endothelial cells (HAECs) were purchased from LONZA. When cells reached 70% to 80% confluence, they were serum-starved for 24 hours and then transferred to an In Vivo 400 hypoxic workstation (Biotrace, Cincinnati, Ohio), followed by replacing prehypoxic medium. Cells were preincubated with soluble (s)RAGE (25 µg/mL), anti-AGE IgG (15 µg/mL), anti-RAGE IgG (15 µg/mL), or AG (50 and 200 µmol/L) for 2 hours22 or the PKCβ inhibitor LY379196 (30 nmol/L), c-Jun NH2-terminal kinase (JNK) inhibitor SP600125 (20 µmol/L), or p38 inhibitor SB203580 (20 µmol/L) for 45 minutes and then subjected to hypoxia.
Small Interference RNA to Knockdown RAGE and JNK
Small interference (si)RNA duplexes against human RAGE were purchased from Ambion. The JNK siRNA was synthesized by Qiagen.23,24 siRNA duplexes against RAGE or JNK were electroporated into HAECs or MAECs using the Nucleofector device (Amaxa). To control for off-target effects of siRNA, a separate well of endothelial cells (ECs) was electroporated with a scramble siRNA as a negative control. After 48 hours, cells were subjected to hypoxia, followed by RNA isolation using TRIzol (Invitrogen).
Real-Time Quantitative PCR and Northern Blot Analysis
Total RNA was extracted from heart or cells using TRIzol reagent (Invitrogen, Rockville, Md). The real-time PCR analysis for Egr-1 and 18S rRNA was performed as described previously.7 For Northern blot, analysis of mouse JE/MCP-1 or β-actin was as described.5
Western Blotting
Membrane protein fractions, nuclear extracts and total proteins were prepared from heart and cells and were subjected to Western blot1,3,6 with rabbit anti–Egr-1 or Sp1 IgG (1:1000; Santa Cruz Biotechnology Inc, Santa Cruz, Calif). To detect membrane protein translocation, blots were incubated with the primary rabbit anti-PKCβI, anti-PKCβII, anti-PKC
, anti-PKC
, or anti-PKC
IgG (1:1000; Santa Cruz Biotechnology Inc), and protein loading was normalized with anti–β-actin IgG (1:10 000, Sigma).25 To detect JNK, blots were incubated with the primary anti–phospho-JNK IgG or anti–total JNK IgG (1:1000; Cell Signaling Technology Inc). In other studies, antibodies to S10026 or high-mobility group box (HMGB)1 (1:200; Stressgen Bioreagents, Victoria, British Columbia, Canada) were used for cultured endothelial cell supernatants.
Electrophoretic Mobility Gel Shift Assay and Antibody Supershift Assay
Crude nuclear extracts were prepared from hypoxic heart or cells,1 and electrophoretic mobility gel shift assay (EMSA) was performed as described.1 For antibody supershift assay, nuclear extracts were preincubated with anti–Egr-1 IgG (Santa Cruz Biotechnology) and then subjected to binding reaction.1
Immunofluorescence
Sections from formalin-fixed, paraffin-embedded heart tissues of mice were deparaffinized and stained with a rabbit polyclonal anti-mouse Egr-1 antibody (1:40; Santa Cruz Biotechnology Inc) and then incubated with a biotinylated goat anti-rabbit IgG (1:200; Vector Laboratories Inc, Burlingame, Calif), followed by incubation with Texas Red–avidin D. The sections were blocked with avidin/biotin blocking solution. The sections were incubated with a goat polyclonal antimouse platelet endothelial cell adhesion molecule-1 (CD31) antibody (1:50; Santa Cruz Biotechnology Inc), and incubated with a biotinylated rabbit anti-goat IgG (1:200; Vector Laboratories Inc), followed by fluorescein–avidin D. A similar procedure was performed on the adjacent section with a nonimmune IgG, and then nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI). The signals of individual and merged images for antigen detection were performed using a LaserSharp 2000 scanning confocal microscope with epifluorescent illumination (Bio-Rad Laboratories Inc) (excitation wavelength 488 nm for fluorescein–avidin D, 568 nm for Texas Red–avidin D).
ELISA for Detection of AGE
When cells reached 90% to 95% confluence, they were serum-starved for 24 hours and then subjected to hypoxia as described above. Supernatants were harvested and stored at –80°C. Cell lysates were prepared using cell lysis buffer (Cell Signaling Technology Inc) for determining protein concentrations. Equal amounts of protein were coated overnight onto an ELISA plate using carbonate-bicarbonate buffer (Sigma). AGE ELISA was performed using T-gel (Pierce) affinity-purified chicken anti-AGE as the primary antibody,27 at a concentration of 30 µg/mL for 3 hours at room temperature. The secondary antibody (anti-chicken IgY) (Sigma) was diluted to 1:10 000 for 1 hour at room temperature. The signals were developed in phosphate-citrate (Sigma) and hydrogen peroxide (Sigma). Ribose glycated albumin was used to prepare the standard curve.
Statistical Analysis
All data are expressed as the means±SEM. Statistical significance was analyzed by ANOVA using commercially available software (Statview, version 5.0.1, Berkeley, Calif). Probability values of <0.05 were considered statistically significant.
| Results |
|---|
|
|
|---|
RAGE+/+ mice were exposed to hypoxia (oxygen, 6%) or normoxia. Real-time PCR analysis of RNA from hearts retrieved from these animals revealed that hypoxia induced an increase in Egr-1 transcripts in a time-dependent manner, with a peak increase at 30 minutes of hypoxia (
28-fold) versus normoxia (Figure 1a; P<0.0001). To address potential roles for RAGE, RAGE+/+ and homozygous RAGE–/– mice were subjected to oxygen deprivation. Compared with hearts from RAGE+/+ mice, Egr-1 mRNA transcripts were significantly lower in RAGE–/– mouse hearts after 30 minutes hypoxia (Figure 1b; P<0.0001). Immunoblotting of nuclear extracts from hypoxic hearts confirmed increased Egr-1 nuclear protein in RAGE+/+ mice hearts after 45 minutes of hypoxia, compared with normoxic controls (Figure 1c; P<0.0001); this was significantly blunted in RAGE–/– mouse hearts (Figure 1c; P<0.0001). Electrophoretic mobility shift analysis of nuclear extracts from RAGE+/+ hearts, but not RAGE–/– hearts, demonstrated an Egr-1 gel shift band with an intensity that increased strongly in hypoxia (Figure 1d; P<0.0001). Supershift assays showed that the hypoxia-induced Egr-1 DNA-binding band in RAGE+/+ hearts was diminished in the presence of Egr-1 antibody (Figure 1e). Because Egr-1 activates downstream mediators of inflammation such as JE/MCP-1 in hypoxia, we tested the effect of RAGE deletion.5 Northern blotting demonstrated that RAGE+/+ mice displayed highly significant,
12-fold upregulation of JE/MCP-1 transcripts in heart tissue after 4 hours of hypoxia (Figure 1f; P<0.0001). In contrast, transcripts for JE/MCP-1 in the hearts of RAGE–/– did not differ in hypoxia versus normoxia (Figure 1f).
|
To determine the principal cell type(s) expressing Egr-1 in the heart subjected to global hypoxia, we performed immunohistochemistry. In hypoxic hearts from RAGE+/+ mice, immunofluorescence experiments using anti–Egr-1 and anti-CD31 IgG demonstrated that Egr-1 protein was localized predominantly in ECs (Figure Ia through Id in the online data supplement, available at http://circres.ahajournals.org).
Membrane Translocation of PKCβII and Activation of JNK in Hypoxic Heart: Effect of RAGE Deletion
In view of previous findings identifying rapid recruitment of PKCβII to upregulation of Egr-1 in the response to hypoxia,3,6 we tested the impact of deletion of RAGE. An increase of PKCβII in RAGE+/+ hearts associated with the membrane fraction was initiated at 10 minutes of hypoxia (Figure 2a; P<0.005) reached an apparent maximum after 15 minutes (Figure 2a; P<0.0001) and remained significantly activated up to 30 minutes of hypoxia (Figure 2a; P<0.005) compared with baseline (Figure 2a). In contrast, immunoblotting with antibodies specific for 4 other PKC isoforms, including PKC
, PKCβI, PKC
, and PKC
(Figure 2b), revealed no change in RAGE+/+ mice after exposure to 10, 15, or 30 minutes of hypoxia versus baseline. RAGE was necessary for rapid membrane translocation of PKCβII, because RAGE–/– mouse hearts displayed an immunoreactive band of PKCβII in the membrane fraction of very low intensity after exposure to hypoxia (Figure 2c; P<0.005). Compared with baseline, PKC isoforms PKC
, PKCβI, PKC
, and PKC
failed to reveal increased membrane translocation resulting from 15 minutes in RAGE+/+ or RAGE–/– mice (Figure 2d) or 10 or 30 minutes (data not shown) of hypoxia. Thus, over the same time course, during which hypoxia activated Egr-1, selective membrane translocation of PKCβII, via RAGE, was observed.
|
In view of roles for PKCβII and RAGE and downstream mitogen-activated protein kinases in environmental stress,3,6–16 we investigated the specific impact of RAGE on JNK activation in hypoxia. Immunoblotting of extracts from hypoxic hearts of RAGE+/+ mice displayed an
5-fold increase in intensity of phospho-JNK, with peak activation at 15 minutes exposure to hypoxia, compared with extracts from normoxic hearts (Figure 2e and 2f). In comparison, RAGE–/– mice hearts displayed a significantly lower increase in phosphorylation of JNK in hypoxia compared with tissue from hypoxic RAGE+/+ hearts; P<0.0001 (Figure 2f).
Probing the Mechanisms Regulating Egr-1 in Hypoxia: Effect of RAGE Deletion in Primary MAECs
Our findings demonstrated that global hypoxia upregulated Egr-1 in the murine heart, particularly in ECs. To probe the specific RAGE-dependent pathways mediating these responses, MAECs were studied. MAECs isolated from RAGE+/+ and RAGE–/– mice were subjected to hypoxia (O2, 0.5%) using an In Vivo 400 hypoxic workstation. Real-time PCR analysis revealed that in RAGE+/+ MAECs, Egr-1 mRNA was increased
20-fold at 15 minutes of hypoxia versus normoxia (Figure 3a and 3b; P<0.0001). In contrast, RAGE–/– MAECs subjected to hypoxia for the same time showed only
3.8-fold increase in Egr-1 transcripts compared with normoxia (Figure 3b). Immunoblotting of nuclear extracts in RAGE+/+ MAECs displayed
6-fold increase in Egr-1 nuclear protein at 30 minutes of hypoxia compared with normoxia (Figure 3c; P<0.0001). In contrast, RAGE–/– MAECs showed an immunoreactive band of very low intensity after exposure to hypoxia, versus the robust response in RAGE+/+ MAECs (Figure 3c; P<0.0001). Electrophoretic mobility shift analysis of nuclear extracts using 32P-labeled consensus oligonucleotide probe for Egr-1 demonstrated a gel shift band with an intensity that increased strongly in response to 30 minutes of hypoxia in RAGE+/+ MAECs (Figure 3d; P<0.0001) but not RAGE–/– MAECs (Figure 3d). In addition, a supershift band shown in nuclear extracts from hypoxic RAGE+/+ MAECs confirmed that hypoxia-induced Egr-1 DNA protein binding was affected by Egr-1 antibody (Figure 3e).
|
Membrane Translocation of PKCβII and Activation of JNK in Primary MAECs After Hypoxia: Effect of RAGE Deletion
We next traced the role of RAGE on PKCβII translocation and JNK activation in primary ECs. When MAECs from RAGE+/+ mice were subjected to hypoxia, PKCβII membrane translocation was significantly increased at 15, 30, and 60 minutes of hypoxia versus normoxia (Figure 4a; P<0.05). However, 4 other PKC isoforms, PKC
, PKCβI, PKC
, and PKC
(Figure 4b), revealed no changes in membrane translocation over this time course. When MAECs from RAGE–/– mice were subjected to hypoxia, there were no changes in membrane protein after 15 minutes of hypoxia by Western blotting using antibodies for detection of PKCβII (Figure 4c), PKC
, PKCβI, PKC
, and PKC
(Figure 4d) compared with baseline.
|
Next, we determined whether deletion of RAGE affected phosphorylation of JNK in hypoxic MAECs. Immunoblotting of extracts from hypoxic MAECs retrieved from RAGE+/+ mice revealed increased phosphorylation of JNK in hypoxia and was sustained up to 2 hours (
6-fold) versus normoxic MAECs (Figure 4e and 4f; P<0.005). In contrast, RAGE–/– MAECs failed to display increased phosphorylation of JNK after 15 minutes of hypoxia (Figure 4f; P<0.005).
Mechanisms by Which RAGE Signaling Upregulates Egr-1 in MAECs
We next sought to establish the specific signals elicited in hypoxia that rapidly evoked RAGE-dependent signaling. We hypothesized that hypoxia generated RAGE ligands and first focused on assessment of AGEs. We measured these species in MAEC supernatants in normoxia or after oxygen deprivation. Interestingly, increased AGE-immunoreactive epitopes were detected in supernatants of RAGE+/+ MAECs by ELISA, beginning at 10 minutes of hypoxia, achieving significance at 15 minutes of hypoxia (Figure 5a; P<0.05) and persisting through 60 minutes of hypoxia versus normoxia control (Figure 5a; P<0.0001). Because RAGE is a multiligand receptor, we investigated whether hypoxia induced release of S100 and HMGB1. Neither S100 nor HMGB1 was detectable by Western blotting in normoxic and hypoxic RAGE+/+ MAEC supernatants, even after they were concentrated 20-fold using Amicon Ultra Centrifugal Filter Devices (data not shown).
|
To directly implicate AGE-RAGE in the downstream events leading to upregulation of Egr-1 in hypoxia, we used specific reagents to block AGE, RAGE, and their interaction in WT ECs exposed to hypoxia. Treatment of ECs with anti-AGE IgG, anti-RAGE IgG or sRAGE, the extracellular ligand-binding domain of RAGE, blocked hypoxia-mediated membrane translocation of PKCβII (Figure 5b), suppressed phosphorylation of JNK (Figure 5c), and upregulation of Egr-1 nuclear protein (Figure 5d) and mRNA (Figure 5e). In addition, hypoxia-stimulated phosphorylation of JNK was blocked by an inhibitor of PKCβ (LY379196) (Figure 5c), and induction of Egr-1 nuclear protein and mRNA was suppressed by inhibitors of PKCβ (LY379196) and JNK (SP600125) (Figure 5d and 5e), but not by an inhibitor of p38 mitogen-activated protein kinase (SB203580) (Figure 5d and 5e). Furthermore, introduction of siRNA to knock-down JNK expression blunted the effect of hypoxia on upregulation of Egr-1; P<0.0001, but had no effect on expression of 18S rRNA (Figure 5e). Introduction of scrambled siRNA had no effect of hypoxia on upregulation of Egr-1 in mouse ECs (Figure 5e).
Effect of the AGE Inhibitor AG on RAGE-Dependent Upregulation of Egr-1: In Vivo and In Vitro Analyses
In view of the striking effects of anti-AGE IgG and sRAGE on suppression of RAGE-dependent Egr-1 upregulation in hypoxia, we next directly tested the effects of the AGE inhibitor AG in vivo and in vitro. First, pretreatment of RAGE+/+ mice with AG (100 mg/kg) for 1 hour by intraperitoneal injection before global hypoxia resulted in a
45% reduction in upregulation of Egr-1 transcripts in the heart (Figure 6a; P<0.0001). Second, in vitro, increased expression of Egr-1 transcripts in hypoxic RAGE+/+ MAECs was significantly reduced by
45 to 55% when those MAECs were preincubated with AG (200 and 50 µmol/L) for 2 hour, compared with that in the absence of AG (Figure 6b; P<0.0001).
|
RAGE Regulates Upregulation of Egr-1 in HAECs
A critical test of these concepts was to address the potential roles for RAGE in regulation of Egr-1 in HAECs in hypoxia. First, to determine whether HAECs released AGEs into supernatants in hypoxia, we measured these species by ELISA in HAEC supernatants in normoxia, or after oxygen deprivation. Analogous to our findings in MAECs, increased AGE-immunoreactive epitopes were detected in supernatants of HAECs, reaching statistical significance at 10 minutes of hypoxia (Figure 7a; P<0.05); and persisting through 60 minutes of hypoxia versus normoxia control (Figure 7a; P<0.0001).
|
To probe the potential roles of AGE-RAGE, we tested this axis in regulation of Egr-1 in hypoxia. As illustrated in Figure 7b, hypoxia (30 minutes) evoked an
7-fold increase in transcripts encoding Egr-1 compared with cells in normoxia (P<0.0001). Consistent with key roles for RAGE and its ligands, pretreatment of the HAECs with sRAGE, anti-AGE, or anti-RAGE IgG resulted in significant suppression of hypoxia-stimulated upregulation of Egr-1 transcripts (P<0.0001). In addition, 2 distinct siRNAs targeting RAGE (siRNA-RAGE1 or siRNA-RAGE2) resulted in significant suppression of Egr-1 transcripts in hypoxia (P<0.0001), whereas scramble siRNA had no effect. Furthermore, to trace the pathways linking hypoxia and RAGE to regulation of Egr-1 in HAECs, LY379196 and 2 inhibitors of JNK signaling (SP600125 and siRNA) were tested. Pretreatment with SP600125, as well as introduction of siRNA to reduce JNK expression and blockade of PKCβ (LY379196), significantly suppressed hypoxia-mediated upregulation of Egr-1 transcripts compared with scramble siRNA (Figure 7b).
| Discussion |
|---|
|
|
|---|
|
The observation that hypoxia stimulates rapid production and cellular release of AGEs by murine and human endothelial cells suggests novel mechanisms by which PKCβII may be recruited. Importantly, non-AGE ligands S100 and non-AGE ligands S100 and HMGB1 were not detected in MAEC supernatants over the same time course in which RAGE-dependent mechanisms regulated Egr-1 in hypoxia. We conclude that within the time course of hypoxia in which upregulation of Egr-1 occurred, only the PKCβII isoform, and not other "classic" PKC isoforms (
and β1) or "novel" isoforms (
and
) of PKC, were found to be translocated to the membrane in the intact heart or in primary endothelial cells, at least in part by AGE-dependent signaling, via RAGE.28 Thus, pathways distinct from diacylglycerol selectively recruit PKCβII in hypoxic stress in vivo and in vitro.28
Disturbances in oxidation states are potent activators of JNK signaling.29 The direct impact of hypoxia, as well as the secondary generation of oxidative stress species via AGE-RAGE interaction,15,16 may stimulate and sustain activation of JNK signaling in hypoxia. In vivo, our studies revealed that hypoxia stimulated rapid activation of JNK in the heart; in isolated primary endothelial cells, in vitro–applied hypoxia stimulated activation of JNK signaling through at least the first 60 minutes. These findings are consistent with very recent studies that have revealed specific pathogenic roles for JNK signaling in ischemia/reperfusion injury. Administration of specific small-molecule or peptide-based JNK inhibitors to animals resulted in significant attenuation of injury induced by ischemia and reperfusion in the heart and brain.30–33 Furthermore, mice deficient in the JNK3 isoform revealed decreased apoptosis in the hippocampus after ischemic brain injury.34 Our data identify RAGE as the key upstream regulator of JNK activation in hypoxia.
It is important to note that cellular fate consequent to activation of JNK may be diverse, from upregulation of inflammatory pathways to activation of cell death programs.35 In the present studies, we illustrated that expression of a downstream target gene of Egr-1, monocyte chemoattractant protein (MCP)-1, was significantly reduced in RAGE–/– mouse hearts retrieved after induction of hypoxia. MCP-1 critically contributes to vascular dysfunction via its mediation of monocyte-endothelial binding and consequent signaling and amplification of proinflammatory mechanisms.36 Thus, although hypoxia sparks key mechanisms in tissue damage via immediate activation of Egr-1, the downstream consequences of this factor amplify perturbation in hypoxia-stressed tissues. Here, we have linked these early and later consequences of hypoxia to RAGE.
In conclusion, we show for the first time that RAGE regulates hypoxia-stimulated membrane translocation of PKCβII and consequent activation of JNK signaling, processes that regulate Egr-1 transcripts and protein in the intact heart and in endothelial cells. RAGE-dependent orchestration of vascular perturbation in oxygen deprivation identifies this molecule as a master regulator of inflammatory stress triggered by hypoxia.
| Acknowledgments |
|---|
Sources of Funding
We gratefully acknowledge grant support provided by United States Public Health Service and the Juvenile Diabetes Research Foundation.
Disclosures
A. M. Schmidt receives research support from TransTech Pharma Inc. and is a member of their Scientific Advisory Board.
| Footnotes |
|---|
| References |
|---|
|
|
|---|
2. Rong Y, Hu F, Huang R, Mackman N, Horowitz JM, Jensen RL, Durden DL, Van Meir EG, Brat DJ. Early growth response gene-1 regulates hypoxia-induced expression of tissue factor in glioblastoma multiforme through hypoxia-inducible factor-1 independent mechanisms. Cancer Res. 2006; 66: 7067–7074.
3. Yan SF, Lu J, Zou YS, Soh-Won J, Cohen DM, Buttrick PM, Cooper DR, Steinberg SF, Mackman N, Pinsky DJ, Stern DM. Hypoxia-associated induction of early growth response-1 gene expression. J Biol Chem. 1999; 274: 15030–15040.
4. Yan SF, Lu J, Xu L, Zou YS, Tongers J, Kisiel W, Mackman N, Pinsky DJ, Stern DM. Pulmonary expression of early growth response-1: biphasic time course and effect of oxygen concentration. J Appl Physiol. 2000; 88: 2303–2309.
5. Yan SF, Fujita T, Lu J, Okada K, Shan Zou Y, Mackman N, Pinsky DJ, Stern DM. Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat Med. 2000; 6: 1355–1361.[CrossRef][Medline] [Order article via Infotrieve]
6. Yan SF, Lu J, Zou YS, Kisiel W, Mackman N, Leitges M, Steinberg S, Pinsky D, Stern D. Protein kinase C-beta and oxygen deprivation. A novel Egr-1 dependent pathway for fibrin deposition in hypoxemic vasculature. J Biol Chem. 2000; 275: 11921–11928.
7. Fujita T, Asai T, Andrassy M, Stern DM, Pinsky DJ, Zou YS, Okada M, Naka Y, Schmidt AM, Yan SF. PKCbeta regulates ischemia/reperfusion injury in the lung. J Clin Invest. 2004; 113: 1615–1623.[CrossRef][Medline] [Order article via Infotrieve]
8. Andrassy M, Belov D, Harja E, Zou YS, Leitges M, Katus HA, Nawroth PP, Yan SD, Schmidt AM, Yan SF. Central role of PKCbeta in neointimal expansion triggered by acute arterial injury. Circ Res. 2005; 96: 476–483.
9. Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S, Hofmann M, Yan SF, Pischetsrieder M, Stern DM, Schmidt AM. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem. 1999; 274: 31740–31749.
10. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM, Schmidt AM. Blockade of RAGE-amphoterin signaling suppresses tumour growth and metastases. Nature. 2000; 405: 354–360.[CrossRef][Medline] [Order article via Infotrieve]
11. Huang JS, Guh JY, Chen HC, Hung WC, Lai YH, Chuang LY. Role of receptor for advanced end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J Cell Biochem. 2001; 81: 102–113.[CrossRef][Medline] [Order article via Infotrieve]
12. Yeh CH, Sturgis L, Haidacher J, Zhang XN, Sherwood SJ, Bjercke RJ, Juhasz O, Crow MT, Tilton RG, Denner L. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes. 2001; 50: 1495–1504.
13. Deora AA, Win T, Vanhaesebroeck B, Lander HM. A redox-triggered ras-effector interaction. Recruitment of phosphatidylinositol 3'-kinase to Ras by redox stress. J Biol Chem. 1998; 273: 29923–29928.
14. Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem. 1999; 274: 19919–19924.
15. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern DM. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem. 1994; 269: 9889–9897.
16. Lander HL, Tauras JM, Ogiste JS, Moss RA, Schmidt AM. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem. 1987; 272: 17810–17814.[CrossRef]
17. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Markowitz GS, Stein G, Bierhaus A, Liliensiek B, Arnold B, Nawroth PP, Stern DM, DAgati VD, Schmidt AM. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol. 2003; 162: 1123–1137.
18. Sakaguchi T, Yan SF, Yan SD, Belov D, Rong LL, Sousa M, Andrassy M, Marso SP, Duda S, Arnold B, Liliensiek B, Nawroth PP, Stern DM, Schmidt AM, Naka Y. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest. 2003; 111: 959–972.[CrossRef][Medline] [Order article via Infotrieve]
19. Lawson CA, Yan SD, Yan SF, Liao H, Zhou YS, Sobel J, Kisiel W, Stern DM, Pinsky DJ. Monocytes and tissue factor promote thrombosis in a murine model of oxygen deprivation. J Clin Invest. 1997; 99: 1729–1738.[Medline] [Order article via Infotrieve]
20. Kazachkov M, Chen K, Babiy S, Yu PH. Evidence for in vivo scavenging by aminoguanidine of formaldehyde produced via semicarbazide-sensitive amine oxidase mediated deamination. J Pharmacol Exp Ther. 2007; 322: 1201–1207.
21. Kobayashi M, Inoue K, Warabi E, Minutesami T, Kodama T. A simple method of isolating mouse aortic endothelial cells. J Atheroscler Thromb. 2004; 12: 138–142.
22. Davis MG, Hagen PO. Alterations in venous endothelial cell and smooth muscle cell relaxation induced by high glucose concentrations can be prevented by aminoguanidine. J Surg Res. 1996; 63: 474–479.[CrossRef][Medline] [Order article via Infotrieve]
23. Gururajan M, Chui R, Karuppan AK, Ke J, Jennings CD, Bondada S. C-Jun-N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells. Blood. 2005; 106: 1382–1391.
24. Li G, Xiang Y, Sabapathy K, Silverman RH. An apoptotic signaling pathway in the interferon antiviral response mediated by RNase L and c-Jun NH2-terminal kinase. J Biol Chem. 2004; 279: 1123–1131.
25. Lee MY, Park SH, Lee YJ, Heo JS, Lee JH, Han HJ. EGF-induced inhibition of glucose transport is mediated by PKC and MAPK signal pathways in primary cultured chicken hepatocytes. Am J Physiol Gastrointest Liver Physiol. 2006; 291: G744–G750.
26. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D, Schmidt AM. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999; 9: 889–901.
27. Bucciarelli LG, Kaneko M, Ananthakrishnan R, Harja E, Lee LK, Hwang YC, Lerner S, Bakr S, Li Q, Lu Y, Song F, Qu W, Gomez T, Zou YS, Yan SF, Schmidt AM, Ramasamy R. Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. Circulation. 2006; 113: 1226–1234.
28. Corbalán-García S, Gómez-Fernández JC. Protein kinase C regulatory domains: the art of decoding many different signals in membranes. Biochem Biophys Acta. 2006; 1761: 633–654.[Medline] [Order article via Infotrieve]
29. Torres M. Mitogen-activated protein kinase pathways in redox signaling. Front Biosci. 2003; 8: d369–d391.[Medline] [Order article via Infotrieve]
30. Guan O, Pei DS, Liu XM, Wang XT, Xu TL, Zhang GY. Neuroprotection against ischemic brain injury by SP600125 via suppressing the extrinsic and intrinsic pathways of apoptosis. Brain Res. 2006; 1992: 36–46.
31. Liao S, Porter D, Scott A, Newman G, Doetschman T, Schulz JJ. The cardioprotective effect of the low molecular weight isoform of fibroblast growth factor-2: the role of JNK signaling. J Mol Cell Cardiol. 2007; 42: 106–120.[CrossRef][Medline] [Order article via Infotrieve]
32. Milano G, Morel S, Bonny C, Samaja M, von Sequesser LK, Nicod P, Vassalli G. A peptide inhibitor of c-Jun NH2-terminal kinase reduces myocardial ischemia-reperfusion injury and infarct size in vivo. Am J Physiol Heart Circ Physiol. 2007; 292: H1828–H1835.
33. Ferrandi C, Ballerio R, Gaillard P, Giachetti C, Carboni S, Vitte PA, Gotteland JP, Cirillo R. Inhibition of c-Jun n-terminal kinase decreases cardiomyocyte apoptosis and infarct size after myocardial ischemia and reperfusion in anaesthetized rats. Br J Pharmacol. 2004; 142: 953–960.[CrossRef][Medline] [Order article via Infotrieve]
34. Pirianov G, Brywe KG, Mallard C, Edwards AD, Flavell RA, Hagberg H, Mehmet H. Deletion of the c-Jun N-terminal kinase 3 gene protects neonatal mice against cerebral hypoxic-ischaemic injury. J Cereb Blood Flow Metab. 2007; 27: 1022–1032.[Medline] [Order article via Infotrieve]
35. Weston CR, Davis RJ. The JNK signal transduction pathway. Curr Opin Cell Biol. 2007; 19: 142–149.[CrossRef][Medline] [Order article via Infotrieve]
36. Miller MD, Krangel MS. Biology and biochemistry of the chemokines: a family of chemotactic and inflammatory cytokines. Crit Rev Immunol. 1992; 12: 17–46.[Medline] [Order article via Infotrieve]
Related Article:
Circ. Res. 2008 102: 864-865.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |